ニュース
The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...
Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...
MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...
Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...
Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...
Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...
The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...
AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...
France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...
That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...
During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and ...
US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has made his first testimonies in front of Congress since he ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する